Significance of CXCR3 expression in gastric low‐grade B‐cell lymphoma of mucosa‐associated lymphoid tissue type for predicting responsiveness to Helicobacter pylori eradication
Open Access
- 21 August 2008
- journal article
- Published by Wiley in Cancer Science
- Vol. 99 (9) , 1769-1773
Abstract
Gastric mucosa‐associated lymphoid tissue (MALT) lymphoma is a distinct low‐grade lymphoma that often regresses upon Helicobacter pylori eradication. It was reported that the chemokine receptor CXCR3 is expressed not only on activated T cells, but also on MALT lymphoma cells, and that CXCR3‐positive B lymphocytes migrate or home to the MALT of MALT lymphoma. In the present study, we aimed to elucidate the correlation between CXCR3 expression and the clinicopathological features of gastric MALT lymphoma, and to determine whether CXCR3 expression was predictive of responsiveness to H. pylori eradication. Sixty‐seven patients with gastric MALT lymphoma in a single‐center study were treated with H. pylori eradication therapy. We evaluated the correlation of CXCR3 expression with response to H. pylori eradication therapy by logistic regression stratified according to potential confounders. Immunohistochemical analysis revealed that 28 of 67 cases (42%) were positive for CXCR3 expression. CXCR3 expression was significantly more prevalent in those without H. pylori infection, advanced‐stage disease, and in those with API2–MALT1 fusion. In overall analysis, those with CXCR3 expression showed a significantly increased risk of non‐responsiveness to H. pylori eradication therapy (odds ratio = 28.6; 95% confidence interval 5.70–143.4) compared to those without CXCR3 expression. This higher risk was observed consistently regardless of sex, API2–MALT1 fusion, H. pylori infection, or clinical stage. We showed that CXCR3 expression was an independent predictive factor for non‐responsiveness to H. pylori eradication therapy in patients with gastric MALT lymphoma. (Cancer Sci 2008; 99: 1769–1773)Keywords
This publication has 24 references indexed in Scilit:
- Molecular subtyping of gastric MALT lymphomas: implications for prognosis and managementGut, 2006
- Long-Term Follow-Up of Gastric MALT Lymphoma After Helicobacter Pylori EradicationJournal of Clinical Oncology, 2005
- Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphomaBlood, 2003
- Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st centuryExpert Review of Anticancer Therapy, 2001
- Complete Remission of Primary High-Grade B-Cell Gastric Lymphoma After Cure of Helicobacter pylori InfectionJournal of Clinical Oncology, 2001
- The Product of the t(11;18), an API2-MLT Fusion, Marks Nearly Half of Gastric MALT Type Lymphomas without Large Cell ProliferationThe American Journal of Pathology, 2000
- API2-MALT1 Chimeric Transcripts Involved in Mucosa-Associated Lymphoid Tissue Type Lymphoma Predict Heterogeneous ProductsThe American Journal of Pathology, 2000
- Cure of Helicobacter pylori Infection and Duration of Remission of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue LymphomaJNCI: Journal of the National Cancer Institute, 1997
- Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas.Journal of Clinical Pathology, 1994
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pyloriThe Lancet, 1993